JP2022553888A - レット症候群の治療のための方法及び組成物 - Google Patents
レット症候群の治療のための方法及び組成物 Download PDFInfo
- Publication number
- JP2022553888A JP2022553888A JP2022552123A JP2022552123A JP2022553888A JP 2022553888 A JP2022553888 A JP 2022553888A JP 2022552123 A JP2022552123 A JP 2022552123A JP 2022552123 A JP2022552123 A JP 2022552123A JP 2022553888 A JP2022553888 A JP 2022553888A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- trophinetide
- daily dose
- administered
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025116586A JP2025148461A (ja) | 2019-10-28 | 2025-07-10 | レット症候群の治療のための方法及び組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927008P | 2019-10-28 | 2019-10-28 | |
| US62/927,008 | 2019-10-28 | ||
| US202063031201P | 2020-05-28 | 2020-05-28 | |
| US63/031,201 | 2020-05-28 | ||
| PCT/US2020/057627 WO2021086892A1 (en) | 2019-10-28 | 2020-10-28 | Methods and compositions for treatment of rett syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116586A Division JP2025148461A (ja) | 2019-10-28 | 2025-07-10 | レット症候群の治療のための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553888A true JP2022553888A (ja) | 2022-12-26 |
| JP2022553888A5 JP2022553888A5 (cg-RX-API-DMAC7.html) | 2023-10-18 |
Family
ID=75715568
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552123A Pending JP2022553888A (ja) | 2019-10-28 | 2020-10-28 | レット症候群の治療のための方法及び組成物 |
| JP2025116586A Pending JP2025148461A (ja) | 2019-10-28 | 2025-07-10 | レット症候群の治療のための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116586A Pending JP2025148461A (ja) | 2019-10-28 | 2025-07-10 | レット症候群の治療のための方法及び組成物 |
Country Status (14)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023287750A1 (en) | 2021-07-12 | 2023-01-19 | Acadia Pharmaceuticals Inc. | Crystalline forms of trofinetide |
| WO2023242844A1 (en) * | 2022-06-15 | 2023-12-21 | Ramot At Tel-Aviv University Ltd. | Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis |
| WO2025262646A1 (en) * | 2024-06-22 | 2025-12-26 | Biophore India Pharmaceuticals Pvt. Ltd | Dosage forms of trofinetide and its pharmaceutically acceptable salt thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6709817B1 (en) * | 1999-09-07 | 2004-03-23 | Baylor College Of Medicine | Method of screening Rett syndrome by detecting a mutation in MECP2 |
| LT2667715T (lt) * | 2011-01-27 | 2017-11-10 | Neuren Pharmaceuticals Limited | Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį |
| CN105358160A (zh) * | 2013-02-20 | 2016-02-24 | 瑟阿瓦斯克公司 | 亚硝酸盐的药物制剂及其用途 |
| SI3024463T1 (sl) * | 2013-07-25 | 2020-08-31 | Neuren Pharmaceuticals Limited | Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj |
| US20150224164A1 (en) * | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| GB2554064B (en) * | 2016-09-01 | 2019-11-20 | Jit Singh Shailinder | An enteral feeding tube |
-
2020
- 2020-10-28 KR KR1020227018117A patent/KR20220106982A/ko active Pending
- 2020-10-28 WO PCT/US2020/057627 patent/WO2021086892A1/en not_active Ceased
- 2020-10-28 JP JP2022552123A patent/JP2022553888A/ja active Pending
- 2020-10-28 AU AU2020376801A patent/AU2020376801A1/en active Pending
- 2020-10-28 CA CA3156680A patent/CA3156680A1/en active Pending
- 2020-10-28 CN CN202080090500.2A patent/CN115335071A/zh active Pending
- 2020-10-28 TW TW109137417A patent/TW202116300A/zh unknown
- 2020-10-28 MX MX2022004785A patent/MX2022004785A/es unknown
- 2020-10-28 EP EP20883589.2A patent/EP4051308A4/en active Pending
- 2020-10-28 IL IL292617A patent/IL292617B2/en unknown
- 2020-10-28 BR BR112022008095A patent/BR112022008095A2/pt unknown
-
2022
- 2022-02-01 US US17/590,496 patent/US20220339138A1/en active Pending
- 2022-04-28 CL CL2022001079A patent/CL2022001079A1/es unknown
- 2022-05-31 CO CONC2022/0007501A patent/CO2022007501A2/es unknown
-
2025
- 2025-07-10 JP JP2025116586A patent/JP2025148461A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| NEUROLOGY, vol. Volume 92, Number 16, JPN6024038594, 16 April 2019 (2019-04-16), pages 1912 - 1925, ISSN: 0005701227 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025148461A (ja) | 2025-10-07 |
| AU2020376801A1 (en) | 2022-06-09 |
| IL292617B1 (en) | 2025-11-01 |
| WO2021086892A1 (en) | 2021-05-06 |
| BR112022008095A2 (pt) | 2022-07-12 |
| TW202116300A (zh) | 2021-05-01 |
| CA3156680A1 (en) | 2021-05-06 |
| US20220339138A1 (en) | 2022-10-27 |
| IL292617A (en) | 2022-07-01 |
| CO2022007501A2 (es) | 2022-08-30 |
| EP4051308A4 (en) | 2023-08-23 |
| EP4051308A1 (en) | 2022-09-07 |
| IL292617B2 (en) | 2026-03-01 |
| KR20220106982A (ko) | 2022-08-01 |
| CL2022001079A1 (es) | 2023-04-21 |
| CN115335071A (zh) | 2022-11-11 |
| MX2022004785A (es) | 2022-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250302851A1 (en) | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation | |
| Lieberman III | Managing anticholinergic side effects | |
| US20220339138A1 (en) | Methods and compositions for treatment of rett syndrome | |
| CA3079259A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| CN112423789A (zh) | 用于治疗抑郁症的艾司氯胺酮 | |
| EP3909609A1 (en) | Methods for treatment of refractory generalized myasthenia gravis | |
| KR20250005175A (ko) | 양극성 장애의 치료를 위한 5-meo-dtm | |
| TW202341995A (zh) | 用於治療cns相關病症之神經活性類固醇 | |
| US20230149332A1 (en) | Methods of treating seizure disorders and prader-willi syndrome | |
| CN114126595A (zh) | 用于治疗抑郁症的艾司氯胺酮 | |
| Wartna et al. | Symptomatic treatment of pollen‐related allergic rhinoconjunctivitis in children: randomized controlled trial | |
| Jablonski | Jablonski's dictionary of medical acronyms & abbreviations | |
| Evans et al. | Efficacy and safety of the melanocortin pan-agonist PL9643 in a phase 2 study of patients with dry eye disease | |
| Egeberg et al. | Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances | |
| Overman et al. | Acamprosate for the adjunctive treatment of alcohol dependence | |
| Mach et al. | Suzetrigine as a Novel Non-opioid Analgesic Drug in Pain Management: A Review of Clinical Evidence and Therapeutic Perspectives. | |
| US10195165B2 (en) | Methods of treating Prader-Willi syndrome | |
| Johannsson et al. | Long-acting hydrocortisone for glucocorticoid replacement therapy | |
| EA051935B1 (ru) | Способы и композиции для лечения синдрома ретта | |
| US20250360148A1 (en) | Solid dispersions of psilocybin | |
| Handa et al. | PSYCHIATRIC EMERGENCIES | |
| Tesfamariam et al. | Oral Presentation: Perception and Utilization of Skin Lightening Agents Among Females of Asmara City: A Lesson for Strengthening Cosmetovigilance | |
| Kraaijvanger et al. | Neuroleptic malignant syndrome after overdose of haloperidol–A case report | |
| Gisbert et al. | REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders | |
| Sada et al. | FRI0218 PREVALENCE, BURDEN OF DISEASE AND HEALTHCARE UTILIZATION AMONG PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) IN JAPAN 2005-2017 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20230906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230906 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230907 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231002 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231002 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240927 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250207 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250710 |